Landscape of Alzheimer's Treatments: Where We Are, Where We’re Going (CME, Physician Assistant CME, CNE)

Release: April 16, 2025
Expiration: April 16, 2027

Target Audience

This activity is intended for biochemists, geriatric psychiatrists, geriatric specialists, molecular and cell biologists, neurologists, neuroscientists, nurses, pharmacologists, primary care physicians, physician assistants, psychiatrists, and radiologists involved in the research and/or care of people with Alzheimer’s and other dementias.

Educational Objective 

After completing this activity, the participant should be better able to:

1. Describe the current landscape of treatments for Alzheimer's disease and where the field is going.

Faculty

Jonathan Graff-Radford, M.D., is the division chair of behavioral neurology at Mayo Clinic in Rochester, Minn., where he evaluates and treats patients with cognitive disorders, including dementia. A professor of neurology at Mayo Clinic College of Medicine and Science, Dr. Graff-Radford also serves as a co-investigator in the Mayo Clinic Alzheimer’s Disease Research Center and the Mayo Clinic Study of Aging. He is the site principal investigator for the Mayo Clinic, Rochester Alzheimer’s Clinical Trials Consortium and faculty member for the Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD). He was awarded the Paul B. Beeson Emerging Leaders Career Development Award in Aging for his research.

Jointly provided by Postgraduate Institute for Medicine and the Alzheimer’s Association.

Planning Faculty

 

Disclosure of Financial Relationships:

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Planners and Managers: The PIM planners and managers have nothing to disclose. The Alzheimer’s Association planners and managers have nothing to disclose.

Faculty Disclosures:

• Jonathan Graff-Radford, MD

• Grant Research Support - Site Investigator for trials sponsored by Eisai and Cognition Therapeutics

• Consultant/Advisory Board - DSMB StrokeNET

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Alzheimer's Association.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physicians

The Postgraduate Institute for Medicine designates this live activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours.

Continuing Physician Assistant Education

Postgraduate Institute for Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 3/1/2027. PAs should only claim credit commensurate with the extent of their participation.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.  The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development.  The information presented in this activity is not meant to serve as a guideline for patient management.  Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.